Invivyd, Inc.
IVVD
NASDAQ·Healthcare·Biotechnology·Mkt cap $243.3M
$0.83
▼ -1.08%
P/E
-2.09
Mkt Cap
$243.3M
52-Wk Range
$0.53–$3.07
52-Week Range
$0.53 - $3.07
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 28.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary neutralizing antibody technology platform
- Strategic partnerships with leading research institutions
- Advanced antibody discovery and optimization capabilities
- Focus on unmet needs in infectious disease treatment
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Phase 3 clinical trial advancement for ADG20
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-19.0% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying IVVD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 13, 2026
Reported EPS of -$0.14 vs -$0.11 consensus (-31.3% surprise). Revenue of $14.3M vs $14.4M expected (-0.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-31.3%
Revenue trend · last 8Q
—
—
—
+421%
+41%
+25%
+22%
+21%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$9.3M
$13.8M
$11.3M
$11.8M
$13.1M
$17.2M
$13.7M
$14.3M
Margins · last 8Q
Gross
91.1%
Operating
—
Profit
-310.8%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Aug 27, 2026
vs Industry
How IVVD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related